Neurofibromatosis Preclinical Consortium (NFPC)
At a Glance
- Status: Completed Consortium
- Year Launched: 2007
- Initiating Organization: Children's Tumor Foundation
- Initiator Type: Nonprofit foundation
- Disease focus:
- Location: North America
In 2007, the Children’s Tumor Foundation (CTF) invested $4 million to launch the Neurofibromatosis Preclinical Consortium (NFPC) to test candidate drug therapies for neurofibromatosis in NF1 and NF2 models; compare the responses of different NF tumors to the same drug; and identify candidate clinical therapies. Through a competitive process, six centers were selected — four for NF1 and two for NF2. NFPC has successfully established a preclinical drug testing pipeline and has formed productive collaborations with industrial partners. NFPC has been CTF’s most significant research investment to date.
2008-2013: Project duration
Structure & Governance
NFPC External Advisory Board (EAB):
Jay Gibbs, Ph.D. (chair), AstraZeneca Pharmaceuticals
Gideon E. Bollag, Ph.D., Plexxikon Inc.
Sara A. Courtneidge, Ph.D., The Burnham Inst. for Medical Research
Michael J. Morin, Ph.D., Oncovia, Inc.
Frank McCormick, Ph.D., University of California, San Francisco
Edward Stern, Esq., legal counsel to the CTF Medical Advisory Committee
Tona Gilmer, Ph.D., GSK Pharmaceuticals
EAB Emeritus Members:
Larry Gelbert, Ph.D., Eli Lilly and Company
Filippo G. Giancotti, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center
Janet M Hock, BDS, Ph.D., Maine Institute for Human Genetics and Health
Christopher L. Moertel, M.D., Children’s Hospitals and Clinics of Minnesota
Roger J. Packer, M.D., Children’s National Medical Center
Children’s Tumor Foundation invested $4 million to launch NFPC.
Sponsors & Partners
Cincinnati Children’s Hospital Medical Center
Fox Chase Cancer Center
Harvard Medical School/Brigham & Women’s Hospital
Ohio State University
University of California, San Francisco